Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

Rhea-AI Summary

Elutia (Nasdaq: ELUT) announced that CEO Dr. Randy Mills and CSO Dr. Michelle Williams will present at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas on June 17–18, 2026.

The June 17 presentation at 2:00 pm PT will cover Elutia’s drug-eluting biomatrix technology aimed at reducing post-surgical infection in implant-based breast reconstruction following mastectomy. A live webcast and company video will be available, and the company will host one-on-one investor meetings during the event.

News Market Reaction – ELUT

+0.36%

6 alerts

+0.36% Session close to close

+4.0% Peak Tracked

-2.2% Trough Tracked

$44.65M Market Cap

1.5x Rel. Volume

In the Jun 12 session, ELUT gained 0.36%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.0% during that session. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights continued outreach to the micro-cap investor community, with management...

Analysis

This announcement highlights continued outreach to the micro-cap investor community, with management presenting on June 17–18, 2026 and emphasizing its drug-eluting biomatrix technology for implant-based breast reconstruction. Investors may contextualize this within recent earnings and regulatory updates that detailed NXT-41/NXT-41x timelines and ongoing strategic reviews. Key factors to watch include clinical and regulatory milestones, progress toward commercialization, and any future updates on product-line divestitures.

Key Figures

Conference dates: June 17–18, 2026 Presentation time: 2:00 p.m. Pacific Time Investor meetings dates: June 17–18, 2026

3 metrics

Conference dates June 17–18, 2026 Planet MicroCap Showcase 2026 presentation window

Presentation time 2:00 p.m. Pacific Time Start time on June 17, 2026

Investor meetings dates June 17–18, 2026 Scheduled one-on-one investor meetings

Historical Context

5 past events · Latest: May 18 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 18	Inducement award grant	Neutral	+1.8%	Granted 48,000 stock options under 2026 Inducement Award Plan.
May 14	Quarterly earnings	Neutral	-1.0%	Reported Q1 2026 results and NXT-41/NXT-41x regulatory timelines.
May 14	Investor conference	Neutral	-1.0%	Announced LD Micro Invitational presentation and 1x1 investor meetings.
Apr 30	Earnings date notice	Neutral	-1.0%	Set date and time for Q1 2026 earnings call and webcast.
Mar 17	Investor conference	Neutral	+1.9%	Announced Sidoti Small-Cap virtual conference presentation and 1x1 meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has mainly been conferences, earnings, and routine corporate updates, typically followed by modest +/-1–2% moves without a strong directional pattern.

Recent Company History

Over the last six months, Elutia has focused on investor outreach and financial reporting. It announced multiple conference presentations in March 2026 and May 2026, all emphasizing its drug-eluting biomatrix technology for implant-based breast reconstruction and infection reduction. Earnings-related releases on May 14, 2026 highlighted Q1 results and NXT-41/NXT-41x progress. An inducement award grant on May 13, 2026 reflected routine equity compensation. Today’s Planet MicroCap presentation continues this pattern of visibility-focused, non-dilutive news flow.

Key Terms

drug-eluting biomatrix, implant-based breast reconstruction, mastectomy, revision surgeries

4 terms

drug-eluting biomatrix medical

"a pioneer in drug-eluting biomatrix technologies, today announced that Dr."

A drug-eluting biomatrix is a medical implant or coating made of biocompatible material that slowly releases a drug at a controlled rate where it is placed in the body, like a sponge that steadily releases medicine into surrounding tissue. For investors, it matters because such technology can improve treatment effectiveness, reduce side effects and repeat procedures, and therefore influence product value, regulatory risk and long-term revenue potential for medical-device and pharmaceutical companies.

implant-based breast reconstruction medical

"address post-surgical infection in implant-based breast reconstruction following mastectomy"

A surgical approach that rebuilds a breast using a manufactured implant—usually saline or silicone—placed under the chest muscle or skin after breast tissue is removed or damaged. For investors, it signals demand for specific medical devices, surgical consumables and related services, and brings exposure to product safety rules, reimbursement policies and litigation risk; think of it like replacing a removed car part with an aftermarket component.

mastectomy medical

"implant-based breast reconstruction following mastectomy—one of the most significant challenges"

Mastectomy is a surgical procedure that removes all or part of breast tissue, usually to treat or prevent breast cancer. Investors follow mastectomy trends because changes in how often or which type of mastectomy is performed can affect demand for related drugs, medical devices, reconstructive services and insurance payouts—think of it like a market signal that shifts which products and services hospitals and patients will need.

revision surgeries medical

"infection remains a leading cause of complications and revision surgeries for patients undergoing"

Revision surgeries are follow-up operations performed to correct, replace, or improve the outcome of a previous surgical procedure—like fixing or upgrading a device that didn’t last or caused problems. For investors, they matter because the frequency of revisions signals product durability, ongoing revenue for device makers and hospitals, potential liability or warranty costs, and future demand for replacement procedures, much like repair work indicates the quality and service needs of a manufactured product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host one-on-one meetings with investors at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas, Nevada on June 17–18, 2026.

During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy—one of the most significant challenges facing patients and surgeons—through its drug-eluting biomatrix technology designed to support safer, more reliable reconstructive outcomes.

The Company will highlight its focus on improving outcomes in implant-based breast reconstruction, where infection remains a leading cause of complications and revision surgeries for patients undergoing reconstruction after breast cancer treatment.

The presentation will begin at 2:00 pm Pacific Time on Wednesday, June 17, 2026, and can be accessed live here: Webcast. Watch our company video on reducing infection risk and commercial adoption. Elutia will also host one-on-one meetings with investors on June 17–18, 2026. To register for the presentation or schedule a one-on-one meeting, visit Planet MicroCap.

About Planet MicroCap

Planet MicroCap Showcase is the premier investor conference dedicated to micro-cap companies, connecting executives with institutional and retail investors through company presentations, one-on-one meetings, and networking events. The annual showcase is held in Las Vegas and draws participants from across the investment community. For more information, visit www.planetmicrocap.com.

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:

Elutia Investor Relations

ir@elutia.com

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/000c457e-8c20-496e-99e5-87559efb4cbb

FAQ

When will Elutia (NASDAQ: ELUT) present at the Planet MicroCap Showcase 2026?

Elutia will present at the Planet MicroCap Showcase 2026 on June 17, 2026, at 2:00 pm Pacific Time. According to Elutia, the event takes place June 17–18, 2026, at the Bellagio in Las Vegas.

What topic will Elutia (ELUT) cover at the Planet MicroCap Showcase 2026 presentation?

Elutia will discuss its drug-eluting biomatrix technology for implant-based breast reconstruction after mastectomy. According to Elutia, the focus is on addressing post-surgical infection and supporting safer, more reliable reconstructive outcomes for breast cancer patients.

Who from Elutia will speak at the Planet MicroCap Showcase 2026 in Las Vegas?

Elutia’s CEO Dr. Randy Mills and CSO Dr. Michelle Williams will present at the conference. According to Elutia, they will lead the main presentation and host one-on-one investor meetings during June 17–18, 2026.

How can investors watch Elutia’s June 17, 2026 Planet MicroCap presentation?

Investors can access Elutia’s June 17, 2026 presentation via a live webcast link. According to Elutia, attendees can also watch a company video on reducing infection risk and learn about commercial adoption of its drug-eluting biomatrix technology.

Will Elutia (ELUT) host one-on-one investor meetings at Planet MicroCap Showcase 2026?

Yes, Elutia will host one-on-one investor meetings on June 17–18, 2026. According to Elutia, investors can register for the presentation or schedule meetings by visiting the Planet MicroCap registration platform.

What clinical need is Elutia targeting with its drug-eluting biomatrix technology discussed on June 17, 2026?

Elutia is targeting post-surgical infection in implant-based breast reconstruction following mastectomy. According to Elutia, infection is a leading cause of complications and revision surgeries for patients undergoing reconstruction after breast cancer treatment.